Encore Medical aims to raise $17.25M in IPO funding for FDA heart device trials. Click here to read the latest analysis on ...

- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible ...

Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...

While other device-based closures have demonstrated notable rates of atrial fibrillation (5.7–6.6%) and device-related adverse events, the NobleStitch™ system's fully suture-mediated approach ...

It has been well established that device closure has, on average, prevented stroke recurrence in people who’ve had patent foramen ovale–associated stroke, but a meta-analysis has drilled down into ...

Abbott announced that the FDA has approved its patent foramen ovale occlusion system for patients with a PFO and prior stroke at risk for recurrent ischemic stroke. According to a company press ...

The population of patients undergoing patent foramen ovale (PFO) closure in the US doesn’t match those of the clinical trials that formed the basis of the US Food and Drug Administration’s approval of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

CHICAGO, Nov 15 (Reuters) - NMT Medical Inc's catheter system that seals a hole in the heart worked no better than drugs to prevent stroke in a study, suggesting physicians perform too many closure ...